Platinum-resistant Ovarian Cancer

YouTube Chemotherapeutic agents video
Chemotherapy Types
alkylating agents, antimetabolites, microtubule targeting agents, topoisomerase, anthracyclines, monoclonal antibodies, others

Targeted therapy
Hormonal therapy (oncology)
Cancer immunotherapy

Caris

Potential benefit

paclitaxel, docetaxel, nab-paclitaxel

gemcitabine

liposomal-doxrubicin

leuprolide, megestrol acetate

doxorubicin, epirubicin

Potential lack of benefit

irinotecan, topotecan

tamoxifen, fulvestrant, letrozole (aromatase inhibitor), anastrozole (anti-aromatase)

fluorouracil, capecitabine, pemetrexed

trastuzumab, pertuzumab

temozolomide, dacarbazine

NCCN

docetaxel 22%

etoposide 27%

gemcitabine 19%

liposomal doxorubicin 26%

paclitaxel weekly 21%

topotecan 20%

altretamine 14%

capecitabine

cyclophosphamide

doxorubicin

ifosfamide 12%

irinotecan

melphalan

oxaliplatin

paclitaxel

nab-paclitaxel 64%

pemetrexed 21%

vinorelbine 20%

bevacizumab 21%

aromatase inhibitors (letrozole, anastrozole)

leuprolide acetate

megestrol acetate

tamoxifen

Platinum-resistant

nab-paclitaxel, docetaxel (anti-microtubule)

gemcitabine (antimetabolites)

doxil (anthracyclines)

leuprolide acetate (Lupron)

megestrol acetate (Megace - Antiandrogen Antiprogestogen)

etoposide 27% (topoisomerase)?

oxaliplatin (alkylating-like)?

vinorelbine 20% (anti-microtubule)?

altretamine 14% (nonclassical alkylating agent)?

ifosfamide 12%, cyclophosphamide, melphalan (alkylating agents)?

pemetrexed 21% (antimetabolites)
topotecan 20%, irinotecan (topoisomerase)
capecitabine (anthracyclines)

Cancer immunotherapy, the new cure, too many


Ipilimumab Yervoy, Bristol-Myers Squibb
Pembrolizumab PD-1 Keytruda, Merck Aceess Program, for Keytruda
Nivolumab PD-1 Opdivo, Expanded Access Program (Compassionate Use), Bristol-Myers Squibb Access Support
Atezolizumab PD-L1 Tecentriq Atezo, Genetech/Roche, news

Prescription assistance programs

Liquid biopsy, ctDNA, Foundation Medicine, Qiagen

UCSF Early Phase Clinical Trials Unit, Early Phase Clinical Trials Unit, Early Phase Clinical Trials, Developmental Therapeutics